

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, November 10, 2006

Hide? **Set Name Query**

Hit Count

DB=PGPB,USPT,JPAB,DWPI; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L12	11 same impoten\$	1
<input type="checkbox"/>	L9	14 or L8	22
<input type="checkbox"/>	L8	11 and L7	20
<input type="checkbox"/>	L7	15 or L6	1490
<input type="checkbox"/>	L6	female near3 sexual dysfunction	1380
<input type="checkbox"/>	L5	female near3 arousal disorder	285
<input type="checkbox"/>	L4	11 same L2	9
<input type="checkbox"/>	L3	11 and L2	296
<input type="checkbox"/>	L2	erect\$ near3 (dysfunction or inabl\$ or problem\$ or disorder or disease)	6258
<input type="checkbox"/>	L1	bFGF or basic fibroblast growth factor	12385

END OF SEARCH HISTORY

\$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspla1633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAPLUS enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAPLUS F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:45:48 ON 10 NOV 2006

=>

=> FIL EMBASE BIOSIS CAPLUS

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		6.51	6.51

FILE 'EMBASE' ENTERED AT 17:04:32 ON 10 NOV 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:04:32 ON 10 NOV 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:04:32 ON 10 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s bFGF or basic fibroblast growth factor
L1 36990 BFGF OR BASIC FIBROBLAST GROWTH FACTOR

=> s impoten?
L2 21530 IMPOTEN?

=> s erectile (3a) (disorder or dysfunction or disease or inab?)
L3 15377 ERECTILE (3A) (DISORDER OR DYSFUNCTION OR DISEASE OR INAB?)

=> s l2 or l3
L4 29587 L2 OR L3

=> s l1 and l4
L5 28 L1 AND L4

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 22 DUP REM L5 (6 DUPLICATES REMOVED)

=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 22 ANSWERS -
CONTINUE? Y(N);y

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2006:269747 CAPLUS <<LOGINID:20061110>>
DN 144:286715

TI Thyroid hormone analogs and their polymeric conjugates, alone or in

combination with other drugs, as modifiers of angiogenesis

IN Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.

PA Ordway Research Institute, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.
DATE			

PI WO 2006031922 A2 20060323 WO 2005-US32813
20050915

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,

BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,

FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP,

KR, KZ,

LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,

MW, MX, MZ,

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,

SD, SE, SG,

SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,

VC, VN,

YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,

GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,

TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,

AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM

PRAI US 2004-943072 A2 20040915

US 2005-670534P P 20050413

AB Disclosed are methods of treating subjects having conditions related to

angiogenesis including administering an effective amt. of a

polymeric form

of thyroid hormone, or an antagonist thereof, to promote or inhibit

angiogenesis in the subject. Comps. of the polymeric forms of

thyroid

hormone, or thyroid hormone analogs, are also disclosed.

Imaging agents

are also claimed for diagnosing a neurodegenerative disease

comprising a

labeled thyroid hormone analog that binds to transthyretin.

L6 ANSWER 2 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier
B.V. All rights reserved on STN DUPLICATE 1

AN 2006186128 EMBASE <<LOGINID::20061110>>
 TI Intracavernosal ***basic*** ***fibroblast*** ***growth***
 factor improves vasoreactivity in the
 hypercholesterolemic rabbit.
 AU Xie D.; Phippen A.M.; Odrionic S.I.; Annex B.H.; Donatucci C.F.
 CS Dr. B.H. Annex, VA Medical Center, 508 Foulton St., Durham,
 NC 27710.
 United States. annex001@mc.duke.edu
 SO Journal of Sexual Medicine, (2006) Vol. 3, No. 2, pp. 223-232.
 Refs: 36
 ISSN: 1743-6095 E-ISSN: 1743-6109
 CY United Kingdom
 DT Journal; Article
 FS 003 Endocrinology
 005 General Pathology and Pathological Anatomy
 028 Urology and Nephrology
 037 Drug Literature Index
 LA English
 SL English
 ED Entered STN: 8 May 2006
 Last Updated on STN: 8 May 2006
 AB Purpose. We determined the effects of intracavernosal
 injection (ICI) of
 recombinant ***basic*** ***fibroblast*** ***growth***
 factor (rbFGF) on corporal tissue in hypercholesterolemic
 rabbits.
 Methods. Twenty New Zealand White rabbits were fed a 1%
 cholesterol diet
 for 6 weeks and were randomly divided into four groups. Group
 1 (N = 5)
 received an ICI of phosphate buffered saline solution (PBS) once
 and again
 3 weeks later. Group 2 (N = 4) received an ICI of 2.5 .mu.g
 rbFGF once
 and PBS 3 weeks later. Group 3 (N = 6) received an ICI of 2.5
 .mu.g rbFGF
 once and again 3 weeks later. Group 4 (N = 5) received an ICI of
 2.5
 .mu.g rbFGF once. All animals were maintained on the high
 cholesterol
 diet until sacrifice, 3 weeks after last injection. Strips of corporal
 tissue were submaximally contracted with norepinephrine, and
 dose-response
 curves were generated to evaluate endothelial-dependent
 (acetylcholine,
 ACH) and endothelial-independent (sodium nitroprusside, SNP)
 vasoreactivity. Protein levels of ***bFGF*** and vascular
 endothelial
 growth factor (VEGF) were assessed by enzyme-linked
 immunosorbent assay.
 Neuronal nitric oxide synthase (nNOS) protein and mRNA were
 detected by
 Western blot and semi-quantitative polymerase chain reaction,
 respectively. Results. Vasoreactivity was improved by
 bFGF
 treatment as shown by higher ED50[-log(M)] of ACH and SNP in
 Groups 2, 3,
 and 4. The expression of ***bFGF*** protein, VEGF protein,
 nNOS
 protein, and mRNA were all increased after ***bFGF***
 treatment.
 Conclusion. ICI of ***bFGF*** improved vasoreactivity in
 hypercholesterolemic rabbit corporal tissue, offering a new
 direction to
 explore for the treatment of ***erectile*** ***dysfunction***.
 .COPYRGT. 2005 International Society for Sexual Medicine.

L6 ANSWER 3 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier
 B.V. All rights
 reserved on STN
 AN 2006252764 EMBASE <<LOGINID::20061110>>
 TI Update on ***erectile*** ***dysfunction*** in prostate cancer
 patients.
 AU Kendirci M.; Beijma J.; Hellstrom W.J.G.
 CS Dr. W.J.G. Hellstrom, Section of Andrology, Department of
 Urology, Tulane
 University Health Sciences Center, 1430 Tulane Avenue, SL-42,
 New
 Orleans, LA 70112, United States. whellst@tulane.edu
 SO Current Opinion in Urology, (2006) Vol. 16, No. 3, pp. 186-195.
 Refs: 72
 ISSN: 0963-0643 CODEN: CUOUEQ
 PUI 0004230720060500000013
 CY United Kingdom
 DT Journal; General Review
 FS 008 Neurology and Neurosurgery
 016 Cancer
 028 Urology and Nephrology
 030 Pharmacology
 037 Drug Literature Index
 LA English
 SL English

ED Entered STN: 21 Jun 2006
 Last Updated on STN: 21 Jun 2006
 AB Purpose of review: Evolution in the management of prostate
 cancer includes
 increased attention being paid to patient quality of life after
 treatment,
 specifically with issues related to sexual function. ***Erectile***
 dysfunction is one of the major concerns of patients
 undergoing
 treatment for prostate cancer. There are several recognized
 factors that
 determine the postoperative incidence of erectile difficulties,
 including
 patient age, degree of cavernosal nerve sparing during surgery,
 cancer
 stage, and associated vascular comorbidities. Early initiation of
 rehabilitation protocols after radical prostatectomy has been
 advocated to
 promote the speed and degree of recovery of erectile function.
 The aim of
 this communication is to review recent initiatives in ***erectile***
 dysfunction restoration after prostate cancer therapy.
 Recent
 findings: In recognition of the neurogenic basis of ***erectile***
 dysfunction after radical prostatectomy, new strategies
 have been
 devised to initiate the rehabilitation process. Type 5
 phosphodiesterase
 inhibitors, vacuum erection devices, and intracavernosal and
 intraurethral
 application of vasoactive agents have all been reported in a
 positive
 light in recent studies. Developments in cavernous nerve graft
 interposition procedures, perioperative neuroprotection
 measures, and
 postoperative neurotrophic treatments aim to preserve prostate
 cancer
 patients' qualities of life. Summary: Data generated from a
 number of
 clinical investigations document that pharmacologic rehabilitation
 programs provide a higher rate of recovery of erectile function
 following
 radical prostatectomy. Both intracavernosal and intraurethral
 applications of vasoactive agents and vacuum devices can
 speed the
 recovery period for return of erectile function. Various
 neuroprotective
 and neurotrophic approaches are thought to provide integral
 roles for the
 maintenance of sexual function in men undergoing prostate
 cancer therapy.
 .COPYRGT. 2006 Lippincott Williams & Wilkins.

L6 ANSWER 4 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier
 B.V. All rights
 reserved on STN
 AN 2006521837 EMBASE <<LOGINID::20061110>>
 TI Neuromodulatory drugs for the radical prostatectomy patient:
 Current and
 future applications.
 AU Webster J.C.; Davila H.H.; Parker J.; Carrion R.E.
 CS Dr. R.E. Carrion, H. Lee Moffitt Cancer Center and Research
 Institute,
 Genitourinary Program, MCCC 4035, 12902 Magnolia Drive,
 Tampa, FL
 33612-9416, United States. carrione@moffitt.usf.edu
 SO Current Sexual Health Reports, (2006) Vol. 3, No. 3, pp. 120-
 124.
 Refs: 44
 ISSN: 1548-3584 E-ISSN: 1548-3592
 CY United States
 DT Journal; General Review
 FS 009 Surgery
 016 Cancer
 022 Human Genetics
 028 Urology and Nephrology
 037 Drug Literature Index
 LA English
 SL English
 ED Entered STN: 7 Nov 2006
 Last Updated on STN: 7 Nov 2006
 AB Prostate cancer is the most common noncutaneous malignancy
 in US men, with
 an estimated 232,000 new cases diagnosed in 2005. Radical
 prostatectomy
 (RP) has proved to be a safe and effective therapy for localized
 prostate
 cancer. However, RP can be associated with some risk of
 morbidity, which
 includes a potential compromise in erectile function. Medical
 therapies
 for ***erectile*** ***dysfunction*** after RP include
 vasoactive

agents and neuromodulatory agents. This review evaluates the potential role of neuromodulatory agents in the post-RP patient. The potential of developing an agent that has a high safety profile and long duration of effectiveness makes these agents attractive alternatives for the future.

Copyright .COPYRGT. 2006 by Current Science Inc.

L6 ANSWER 5 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AN 2006129021 EMBASE <<LOGINID::20061110>>

TI Hope springs eternal: Cavemosal nerve regeneration.

AU Syme D.B.Y.; Corcoran N.M.; Bouchier-Hayes D.M.; Costello A.J.

CS D.B.Y. Syme, Department of Urology, Royal Melbourne

Hospital, Grattan St,

Parkville, Vic. 3050, Australia. david.syme@mh.org.au

SO BJU International, (2006) Vol. 97, No. 1, pp. 17-21.

Refs: 29

ISSN: 1464-4096 E-ISSN: 1464-410X CODEN: BJINFO

CY United Kingdom

DT Journal: General Review

FS 008 Neurology and Neurosurgery

016 Cancer

021 Developmental Biology and Teratology

027 Biophysics, Bioengineering and Medical Instrumentation

028 Urology and Nephrology

LA English

ED Entered STN: 12 Apr 2006

Last Updated on STN: 12 Apr 2006

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L6 ANSWER 6 OF 22 BIOSIS COPYRIGHT (c) 2006 The

Thomson Corporation on STN

AN 2006:132204 BIOSIS <<LOGINID::20061110>>

DN PREV200600144388

TI Methods and compositions for preventing and treating male

erectile

dysfunction and female sexual arousal disorder.

AU Lue, Tom F. [Inventor]; Lin, Ching-Shwun [Inventor]; Kan, Yuet

W.

[Inventor]

CS Hillsborough, CA USA

ASSIGNEE: The Regents of the University of California

PI US 06852323 20050208

SO Official Gazette of the United States Patent and Trademark

Office Patents,

(FEB 8 2005)

CODEN: OGUPE7. ISSN: 0098-1133.

DT Patent

LA English

ED Entered STN: 22 Feb 2006

Last Updated on STN: 22 Feb 2006

AB This invention relates generally to the field of urology. In

particular,

the invention provides a method for preventing or treating male

erectile ***dysfunction*** or female sexual arousal

disorder,

which method comprises administering an effective amount of

vascular

endothelial growth factor (VEGF), brain-derived neurotrophic

factor

(BDNF), ***basic*** ***fibroblast*** ***growth***

factor (***bFGF***), or a functional derivative or

fragment

thereof, or a nucleic acid encoding said VEGF, BDNF or

bFGF, or

functional derivative or fragment thereof, or an agent that

enhances

production and/or erection or sexual arousal stimulating function

of said

VEGF or BDNF or ***bFGF*** to a mammal, wherein such

prevention or

treatment is desirable, thereby preventing or treating said male

erectile ***dysfunction*** or female sexual arousal

disorder

in said mammal. Combinations, combinatorial methods and kits

for

preventing or treating male ***erectile*** ***dysfunction*** or

female sexual arousal disorder are also provided. STATEMENT

OF RIGHTS TO

INVENTIONS MADE UNDER FEDERALLY SPONSORED

RESEARCH This invention is

supported by Grant No. DK45370 and DK51374 of the National

Institutes of

Health. The United States government may have certain rights

in this

invention. The disclosure of the above-described application is

incorporated herein by reference in its entirety.

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:283330 CAPLUS <<LOGINID::20061110>>

DN 142:330277

TI Thyroid hormone analogs and their polymeric conjugates, alone

or in

combination with other drugs, as modifiers of angiogenesis

IN Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.

PA Ordway Research Institute, USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO.

DATE

PI WO 2005027895 A2 20050331 WO 2004-US30583

20040915

WO 2005027895 A3 20050506

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,

BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,

FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,

KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,

SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,

ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,

DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,

RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

MR, NE,

SN, TD, TG

AU 2004273986 A1 20050331 AU 2004-273986

20040915

CA 2539288 AA 20050331 CA 2004-2539288

20040915

EP 1670449 A2 20060621 EP 2004-784443

20040915

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,

MC, PT,

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-502721P P 20030915

WO 2004-US30583 W 20040915

AB Disclosed are methods of treating subjects having conditions

related to

angiogenesis including administering an effective amt. of a

polymeric form

of thyroid hormone, or an antagonist thereof, to promote or inhibit

angiogenesis in the subject. Comps. of the polymeric forms of

thyroid

hormone, or thyroid hormone analogs, are also disclosed.

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1132649 CAPLUS <<LOGINID::20061110>>

DN 143:411065

TI Drug delivery systems containing drugs in a water soluble

composition

immersed in a hydrophobic medium for improved penetration

through

biological barriers

IN Ben-Sasson, Shmuel A.

PA Israel

SO U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO.

DATE

PI US 2005232981 A1 20051020 US 2005-105763

20050414

WO 2006097793 A2 20060921 WO 2005-IB4183

20050414

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,

BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,

FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP,

KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

MX, MZ, NA,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,

SG, SK, SL,

SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA,

ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG,
KZ, MD, RU, TJ, TM

PRAI US 2004-562345P P 20040415

OS MARPAT 143:411065

AB This invention relates to novel penetrating compns. including one or more effectors included within a water sol. compn., immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compns. to affected subjects.

For example, a compn. with improved insulin across epithelial barrier

contained insulin, spermine, phytic acid, sodium dodecanoate, octanol/geraniol, mineral oil/medium chain triglycerides/castor oils.

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:546880 CAPLUS <<LOGINID::20061110>>

DN 143:83457

TI compositions facilitating translocation of therapeutic effector across

biol. barrier comprising hydrophobic agent, counter ion,

penetrating

peptide, and/or protease inhibitor

IN Ben-Sasson, Shmuel A.; Cohen, Einat

PA Israel

SO U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 665,184.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.
------------	------	------	-----------------

DATE			
------	--	--	--

PI US 2005136103	A1	20050623	US 2004-942300
------------------	----	----------	----------------

20040916			
----------	--	--	--

US 2004146549	A1	20040729	US 2003-665184
---------------	----	----------	----------------

20030917			
----------	--	--	--

US 7115707	B2	20061003	
------------	----	----------	--

US 2005058702	A1	20050317	US 2003-664989
---------------	----	----------	----------------

20030917			
----------	--	--	--

PRAI US 2003-503615P P 20030917

US 2003-664989 A2 20030917

US 2003-665184 A2 20030917

US 2002-355396P P 20020207

WO 2003-IB968 A2 20030207

OS MARPAT 143:83457

AB This invention relates to novel pharmaceutical compns. capable of

facilitating penetration of at least one effector across biol. barriers.

The compns. may comprise therapeutic effectors, hydrophobic agents,

counter ions, protein stabilizers, penetrating peptides, surface active

agents, and protease inhibitors. Disclosed are methods for

producing the

compns. of the invention, and their uses. The invention also

relates to

methods of treating or preventing diseases by administering

these compns.

to affected subjects, and methods of vaccination.

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on

STN

AN 2005:238432 CAPLUS <<LOGINID::20061110>>

DN 142:303641

TI Compositions capable of facilitating penetration across a

biological

barrier

IN Ben-Sasson, Shmuel A.; Cohen, Einat

PA Israel

SO U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.
------------	------	------	-----------------

DATE			
------	--	--	--

PI US 2005058702 A1 20050317 US 2003-664989

20030917

US 2005136103 A1 20050623 US 2004-942300

20040916

AU 2004317954 A1 20051013 AU 2004-317954

20040917

CA 2539043 AA 20051013 CA 2004-2539043

20040917

WO 2005094785 A2 20051013 WO 2004-IB4452

20040917

WO 2005094785 A3 20060323

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,

BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,

FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,

KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,

SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,

ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,

DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,

RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

MR, NE,

SN, TD, TG

EP 1670500 A2 20060621 EP 2004-821561

20040917

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,

MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,

PL, SK, HR

PRAI US 2003-503615P P 20030917

US 2003-664989 A2 20030917

US 2003-665184 A2 20030917

WO 2004-IB4452 W 20040917

AB This invention relates to novel pharmaceutical compns. for delivery of

biol. active mols., such as polypeptides, drugs and other therapeutic

agents, across various biol. barriers mixing one or more effectors (anionic impermeable mols.) with a counter ion to the effector (a

liq. forming cation). The invention also relates to methods of treating or

preventing diseases by administering pharmaceutical compns. to affected

subjects. For example, an ionic liq. forming cation was used to enable

the translocation of insulin across an epithelial barrier. A compn. contg. recombinant human insulin and an ionic liq. forming

cation, e.g., 1-butyl-3-methylimidazolium chloride, together with phytic acid, Pluronic

F68, aprotinin, Solutol HS-15, and N-acetylcysteine was administered

rectally or by injection into an intestinal loop of a test animal, e.g., a

mouse. Blood glucose levels decrease in relation to the amt. of insulin

absorbed from the intestine into the bloodstream (i.e., in an amt. that

correlates to the amt. of insulin absorbed). Thus, this drug delivery

system can replace the need for insulin injections, thereby providing an

efficient, safe and convenient route of administration for diabetes patients.

L6 ANSWER 11 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier

B.V. All rights reserved on STN

AN 2005128060 EMBASE <<LOGINID::20061110>>

TI Effect of ***basic*** ***fibroblast*** ***growth***

factor incorporating gelatin microspheres on erectile

function in

the diabetic rat.

AU Suetom T.; Hisasue S.-I.; Sato Y.; Tabata Y.; Akaza H.;

Tsukamoto T.

CS S.-I. Hisasue, Department of Urology, Sapporo Medical

University, School

of Medicine, S1-W16, Chuo-ku, Sapporo, Hokkaido, 060-8543,

Japan.

hisasue@sapmed.ac.jp

SO Journal of Urology, (2005) Vol. 173, No. 4, pp. 1423-1428.

Refs: 20

ISSN: 0022-5347 CODEN: JOURAA

CY United States
 DT Journal; Article
 FS 003 Endocrinology
 028 Urology and Nephrology
 029 Clinical Biochemistry
 030 Pharmacology
 037 Drug Literature Index
 LA English
 SL English
 ED Entered STN: 7 Apr 2005
 Last Updated on STN: 7 Apr 2005
 AB Purpose: We report the potential of ***basic***
 fibroblast
 growth ***factor*** (***bFGF***) incorporating gelatin
 microspheres to preserve erectile function in a diabetic rat model.
 Materials and Methods: A total of 48 adult male rats were divided
 into 3
 groups, namely control (nondiabetic rats), diabetes mellitus (DM)
 (diabetic rats that received gelatin microspheres with saline) and
 bFGF (diabetic rats that received gelatin microspheres
 with
 bFGF). After 4 and 8 weeks we examined
 intracavernous pressure
 responses with electrical stimulation to the cavernous nerve. For
 histological examination of the penis we performed Azan-Mallory
 staining
 for smooth muscle and collagen, and immunohistochemistry for
 endothelial
 nitric oxide synthase (NOS) in endothelium and neuronal NOS in
 cavernous
 nerve fiber. Results: Although the intracavernous pressure
 response was
 significantly lower in the DM group than in the control group,
 pressure in
 the ***bFGF*** group was maintained at the normal level
 found in
 controls. Azan-Mallory staining showed a mass decrease in
 smooth muscle
 in cavernous tissue in the DM group. However, that in the
 bFGF
 group was maintained. There was no significant difference in
 endothelial
 NOS positive areas and the distribution of the diameter of
 neuronal NOS
 positive nerve fibers in cavernous tissue among the 3 groups.
 Conclusions: We report the maintenance of erectile function with
 bFGF incorporating gelatin microspheres in diabetic rats.
 The
 rationale of this maneuver is smooth muscle preservation by the
 long-term
 release of ***bFGF*** . This is a novel therapeutic option that
 is
 clinically applicable for diabetes induced ***erectile***
 dysfunction . Copyright .COPYRG. 2005 by American
 Urological
 Association.

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on
 STN
 AN 2004:20807 CAPLUS <<LOGINID::20061110>>
 DN 140:99589
 TI Use of peptides derived from junctional adhesion molecules to
 permeabilize
 mucosa for improved efficiency of mucosal delivery of
 therapeutic
 compounds
 IN Quay, Steven C.
 PA Natesth Pharmaceutical Company, Inc., USA
 SO PCT Int. Appl., 426 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN,CNT 1
 PATENT NO. KIND DATE APPLICATION NO.
 DATE
 PI WO 2004003145 A2 20040108 WO 2003-US19994
 20030624
 WO 2004003145 A3 20040610
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,
 CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB,
 GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
 NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA,
 UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
 SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 CA 2487712 AA 20040108 CA 2003-2487712
 20030624
 AU 2003279750 A1 20040119 AU 2003-279750
 20030624
 US 2004077540 A1 20040422 US 2003-601953
 20030624
 EP 1539208 A2 20050615 EP 2003-742185
 20030624
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
 MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,
 SK
 JP 2005537244 T2 20051208 JP 2004-517800
 20030624
 ZA 2004010287 A 20051118 ZA 2004-10287
 20041221
 PRAI US 2002-392512P P 20020628
 WO 2003-US19994 W 20030624
 AB Methods of improving the permeability of mucosal epithelia to
 improve the
 efficiency of transmucosal delivery of drugs are described.
 Permeability
 is improved by modulating epithelial junction structure or physiol.
 of the
 mucosa using a peptide derived from one of the proteins involved
 in the
 junction, such as junctional adhesion mols. (JAMs), occludins, or
 claudins. The permeabilizing agent is typically a peptide or
 peptide
 analog or mimetic, often selected or derived from an extracellular
 domain
 of a mammalian JAM, occludin or claudin protein. Identification
 of
 candidate peptides derived from junctional adhesion mol. JAM-1,
 claudins
 and occludins is demonstrated. The effects of the peptides were
 tested in
 a com. airway epithelium model. Tests in adult male volunteers
 showed a
 significant improvement in the delivery of human interferon .beta.
 across
 the nasal mucosa when a peptide derived from JAM-1 was
 included in an
 intranasal formulation.
 L6 ANSWER 13 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier
 B.V. All rights
 reserved on STN
 AN 2004360286 EMBASE <<LOGINID::20061110>>
 TI Anagrelide: A decade of clinical experience with its use for the
 treatment
 of primary thrombocythaemia.
 AU Petrides P.E.
 CS Dr. P.E. Petrides, Department of Medicine, University of
 Munich Medical
 School, Hematology Oncology Center, Zweibrückenstr. 2,
 80331 Munich,
 Germany. Petrides@onkologiemuenchen.de
 SO Expert Opinion on Pharmacotherapy, (2004) Vol. 5, No. 8, pp.
 1781-1798.
 Refs: 132
 ISSN: 1465-6566 CODEN: EOPHF7
 CY United Kingdom
 DT Journal; General Review
 FS 025 Hematology
 030 Pharmacology
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 038 Adverse Reactions Titles
 039 Pharmacy
 LA English
 SL English
 ED Entered STN: 9 Sep 2004
 Last Updated on STN: 9 Sep 2004
 AB Primary thrombocythaemia (PT) is the most frequent among
 the rare chronic
 myeloproliferative disorders. Life expectancy is determined by
 thromboembolic and haemorrhagic complications, which can be
 prevented by
 cytoreductive therapy. For a long time, hydroxyurea has been
 considered
 as the therapeutic gold standard. However, hydroxyurea
 treatment is not
 lineage-specific, may not be tolerated because of adverse effects
 (skin,
 gastrointestinal tract) and is leukaemogenic when sequentially
 used with

other DNA-targeting drugs. Hence, anagrelide was welcomed in 1988 when it was first described as being efficient at normalising elevated platelet counts, specific for megakaryocytes and non-mutagenic. Since then, anagrelide has been approved in the US and Canada (Agrylin.RTM., Shire Pharmaceuticals) as well as in Austria and other countries of the EU (Thromboreductin.RTM., AOP Orphan Pharmaceuticals). Clinical Phase III trials (PT1 and ANAHYDRET) are underway to directly compare the efficacy and safety of anagrelide and hydroxyurea. .COPYRG.T. 2004 Ashley Publications Ltd.

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:396441 CAPLUS <<LOGINID::20061110>>
DN 138:396636

TI Methods and compositions for preventing and treating male ***erectile***

dysfunction and female sexual arousal disorder

IN Lue, Tom F.; Lin, Ching-shwun; Kan, Yuet W.; Carroll, Peter
PA USA

SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 909,544.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.
PI US 2003096747	A1	20030522	US 2002-155785

DATE

20020523			
US 2002160951	A1	20021031	US 2001-909544

20010719

US 6852323	B2	20050208	
US 2004180830	A1	20040916	US 2004-806515

20040322

US 2005233962	A1	20051020	US 2005-40947
---------------	----	----------	---------------

20050121

PRAI US 2000-220031P P 20000721

US 2001-909544 A2 20010719

US 2002-155785 A3 20020523

AB The invention provides a method for preventing or treating male ***erectile*** ***dysfunction*** or female sexual arousal disorder

by administering an effective amt. of one or more factors from a group of

factors including vascular endothelial growth factor, brain-derived neurotrophic factor, ***basic*** ***fibroblast*** ***growth*** ***factor***, neurotrophin-3, neurotrophin-4, or angiopoietin-1,

wherein the factor is a full length protein or a nucleic acid encoding the factor,

or a functional deriv. or fragment thereof, or an agent that enhances

prodn. and/or male erection or female sexual arousal stimulating function

of the factor(s). Combinations, kits, and combinatorial methods are also

provided. Also claimed is a method to identify compds. promoting growth

of cavernous nerves from major pelvic ganglia.

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:334645 CAPLUS <<LOGINID::20061110>>

DN 138:348752

TI Sense mRNA therapy using stabilized mRNA

IN Wiederholt, Kristin; Woolf, Tod M.; Taylor, Margaret
PA Lahive & Cockfield, LLP, USA

SO U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.
PI US 2003083272	A1	20030501	US 1998-156323

DATE

19980918			
PRAI US 1997-59371P	P	19970919	

AB The invention describes methods for the stabilization of mRNA. These

alterations increase stability of mRNA and enable its use in sense RNA

therapy to transiently express proteins in a cell. Methods are provided

for making such modifications, as are compns. comprising such modifications, and the use of such compns. in treating disease states.

L6 ANSWER 16 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

DUPLICATE 3

AN 2003292152 EMBASE <<LOGINID::20061110>>

TI Systemic ***basic*** ***fibroblast*** ***growth*** ***factor*** induces favorable histological changes in the

corpus

cavernosum of hypercholesterolemic rabbits.

AU Dai Q.; Silverstein A.D.; Davies M.G.; Hagen P.-O.; Donatucci C.F.; Annex

B.H.

CS B.H. Annex, Division of Cardiology, Durham Vet. Aff./Duke Univ. Med. C.,

Box 111A, 508 Fulton St., Durham, NC 27710, United States

SO Journal of Urology, (1 Aug 2003) Vol. 170, No. 2 I, pp. 664-668.

Refs: 20

ISSN: 0022-5347 CODEN: JOURAA

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

018 Cardiovascular Diseases and Cardiovascular Surgery

028 Urology and Nephrology

030 Pharmacology

037 Drug Literature Index

LA English

SL English

ED Entered STN: 10 Aug 2003

Last Updated on STN: 10 Aug 2003

AB Purpose: Hypercholesterolemia causes ***erectile***

dysfunction that is associated with abnormalities in

vascular

smooth muscle and endothelial cells. We determined the effects of

basic ***fibroblast*** ***growth*** ***factor*** (***bFGF***) on corporeal tissue in hypercholesterolemic

rabbits.

Materials and Methods: A total of 16 New Zealand White rabbits were fed a

1% cholesterol diet for 6 weeks and were randomly divided into 3 groups.

Group 1 (5 rabbits) received 2.5 .mu.g recombinant ***bFGF*** intravenously once and again 3 weeks later. Group 2 (6 rabbits) received

2.5 .mu.g ***bFGF*** intravenously once and placebo 3 weeks later.

Group 3 (5 rabbits) received placebo intravenously each time. Rabbits

were continuously fed a 1% cholesterol diet and sacrificed 3 weeks after

the last treatment. Smooth muscle, endothelial cell and collagen content

were assessed by immunohistochemistry and histochemical staining of

corporeal tissue. Vascular endothelial growth factor (VEGF) protein and

mRNA expression were assessed by enzyme-linked immunosorbent assay and

reverse transcriptase-polymerase chain reaction. Results: Corporeal

smooth muscle content was greater in groups 1 and 2 (35.24% .+ 4.25% and

24.79% .+ 3.39%, p <0.01) vs group 3 (19.68% .+ 2.94%, vs groups 1 and

2 p <0.001 and <0.05, respectively). Endothelial cell and collagen

content were similar among the groups. VEGF protein was increased in

group 1 vs group 2 (97.90 .+ 26.00 vs 57.03 .+ 14.99 pg/ml, p <0.01)

and vs group 3 (39.93 .+ 15.08, p <0.01). There was no statistical

difference between groups 2 and 3. VEGF mRNA expression was similar among

the groups. Conclusions: Systemic ***bFGF*** increases smooth muscle

content and VEGF protein in hypercholesterolemic rabbit corporeal tissue.

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:89855 CAPLUS <<LOGINID::20061110>>

DN 136:129429

TI Methods and compositions for preventing and treating male ***erectile***

dysfunction and female sexual arousal disorder using VEGF, BDNF,

or ***bFGF***

IN Lue, Tom F.; Lin, Ching-Shwun; Kan, Yuet W.

PA USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.
------------	------	------	-----------------

PI WO 2002007757	A2	20020131	WO 2001-US22970
20010719			
WO 2002007757	A3	20030918	
WO 2002007757	C2	20040506	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1365794	A2	20031203	EP 2001-957212
20010719			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI US 2000-220031P	P	20000721	
WO 2001-US22970	W	20010719	

AB This invention relates generally to the field of urol. In particular, the invention provides a method for preventing or treating male ***erectile*** ***dysfunction*** or female sexual arousal disorder, which method comprises administering an effective amt. of vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), ***basic*** ***fibroblast*** ***growth*** ***factor*** (***bFGF***), or a functional deriv. or fragment thereof, or a nucleic acid encoding said VEGF, BDNF or ***bFGF***, or functional deriv. or fragment thereof, or an agent that enhances prodn. and/or erection or sexual arousal stimulating function of said VEGF or BDNF or ***bFGF*** to a mammal, wherein such prevention or treatment is desirable, thereby preventing or treating said male ***erectile*** ***dysfunction*** of female sexual arousal disorder in said mammal. Combinations, combinatorial methods and kits for preventing or treating male ***erectile*** ***dysfunction*** or female sexual arousal disorder are also provided.

L6 ANSWER 18 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2002:422159 BIOSIS <<LOGINID::20061110>>
DN PREV200200422159

TI Nitric oxide synthase and angiogenic growth factor expressions in the penis of an animal model of type 2 diabetes.

AU Jesmin, Subrina [Reprint author]; Sakuma, Ichiro [Reprint author];

Hattori, Yuichi; Kitabatake, Akira [Reprint author]
CS Department of Cardiovascular Medicine, Hokkaido University Graduate School

of Medicine, Sapporo, 060-8638, Japan
SO Nitric Oxide, (June, 2002) Vol. 6, No. 4, pp. 406. print.

Meeting Info.: Second International Conference on Biology, Chemistry and

Therapeutic Applications. Prague, Czech Republic. June 16-20, 2002.

ISSN: 1089-8603.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 7 Aug 2002

Last Updated on STN: 7 Aug 2002

L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:265259 CAPLUS <<LOGINID::20061110>>
DN 134:276162

TI Method of treating ***erectile*** ***dysfunction*** by administering an angiogenic growth factor such as VEGF or active fragment or mimetic thereof

IN Donatucci, Craig; Miller, Julie M.

PA Duke University, USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.
------------	------	------	-----------------

PI WO 2001024809	A1	20010412	WO 2000-US26782
20000929			
W: AU, CA, JP			
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
CA 2386480	AA	20010412	CA 2000-2386480
20000929			
EP 1223957	A1	20020724	EP 2000-967083
20000929			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
US 2004033944	A1	20040219	US 2002-315248
20021210			
PRAI US 1999-157053P	P	19991001	
US 2000-675659	B1	20000929	
WO 2000-US26782	W	20000929	

AB The present invention relates, in general, to ***erectile*** ***dysfunction*** and, in particular, to a method of treating or preventing dysfunction of penile, clitoral or vaginal erectile tissue by

administering an angiogenic growth factor, such as vascular endothelial growth factor (VEGF), or active fragment thereof or mimetic thereof.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:167844 CAPLUS <<LOGINID::20061110>>
DN 134:227368

TI Nitric oxide-producing polymeric hydrogel materials

IN Hill-West, Jennifer L.; Bohl, Kristyn Simcha

PA Rice University, USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.
------------	------	------	-----------------

PI WO 2001015738	A2	20010308	WO 2000-US24058
20000901			
WO 2001015738	A3	20020131	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2353531	AA	20010308	CA 2000-2353531
20000901			
EP 1194171	A2	20020410	EP 2000-959750
20000901			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO			

PRAI US 1999-152054P P 19990902

WO 2000-US24058 W 20000901

AB Hydrogels releasing or producing NO, most preferably photopolymerizable

biodegradable hydrogels capable of releasing physiol. amts. of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile ***erectile*** ***dysfunction*** or other conditions where NO plays a significant role. The hydrogels are typically formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero-dispersion or soln., which is polymd. to form a hydrogel material, that in the latter case can be a semi-interpenetrating network or interpenetrating network. Comps. to be released can be phys. entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. The hydrogel can be formed by ionic and/or covalent crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material.

L6 ANSWER 21 OF 22 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 4

AN 2000371347 EMBASE <<LOGINID::20061110>>
TI Effect of a Chinese herbal medicine mixture on a rat model of hypercholesterolemic ***erectile*** ***dysfunction***

AU Bakirdioglu M.E.; Hsu K.; El-Sakka A.; Sievert K.-D.; Lin C.S.; Lue T.F.

CS T.F. Lue, Department of Urology, University of California, San Francisco, CA 94143, United States

SO Journal of Urology, (2000) Vol. 164, No. 5, pp. 1798-1801. .
Refs: 12

ISSN: 0022-5347 CODEN: JOURAA

CY United States

DT Journal; Article

FS 028 Urology and Nephrology

037 Drug Literature Index

LA English

SL English

ED Entered STN: 16 Nov 2000

Last Updated on STN: 16 Nov 2000

AB Purpose: We examine the effect of a Chinese herbal medicine mixture on

erectile function in a rat model of hypercholesterolemic

erectile

dysfunction. Materials and Methods: In this study 32, 3-month-old

Sprague-Dawley rats were used. The 8 control animals were fed a normal

diet and the remaining 24 were fed 1% cholesterol diet for 4

months.

After 2 months herbal medicine was added to the drinking water of the

treatment group of 16 rats but not the cholesterol only group of 8.

Of

the 16 rats 8 received 25 mg./kg. per day (group 1) and 8

received 50

mg./kg. per day (group 2) of Chinese herbal medicine mixture.

Serum

cholesterol levels were measured at 2 and 4 months. At 4

months erectile

function was evaluated with cavernous nerve electrostimulation

in all

animals. Penile tissues were collected for electron microscopy,

and to

perform Western blot for endothelial nitric oxide synthase,

neuronal

nitric oxide synthase, ***basic*** ***fibroblast***

growth

factor (***bFGF***) and caveolin-1. Results: Serum cholesterol levels were significantly higher in animals fed the 1% cholesterol diet compared to controls at 2 and 4 months.

Nevertheless,

there was no significant difference among group 1 (145 +/- 30

mg./dl.),

group 2 (157 +/- 20) and the cholesterol only group (143 +/- 15).

Systemic arterial pressure was not significantly different between the

animals that were fed the 1% cholesterol diet and the controls.

During

electrostimulation of the cavernous nerve peak sustained intracavernous pressure was significantly lower in the cholesterol only group (50 +/- 23 cm. H2O) compared to the control group. Conversely erectile function was not impaired in the herbal medicine treated rats. Electron microscopy showed many caveolae with fingerlike processes in the cavernous smooth muscle and endothelial cell membranes in control and treated rats but not in the cholesterol only group of rats. Western blot did not show a difference among groups in protein expression for endothelial nitric oxide synthase and neuronal nitric oxide synthase in penile tissue but caveolin-1 and ***bFGF*** protein expression was significantly higher in groups 1 and 2 than in the cholesterol only and control groups. Conclusions: Rats developed ***erectile*** ***dysfunction*** after being fed a 1% cholesterol diet for 4 months. Although serum cholesterol levels were similar in the cholesterol only rats and those treated with Chinese herbal medicine mixture, erectile response was significantly better in the treated group. The mechanism of the herbal medicine is unknown. High levels of ***bFGF*** and caveolin-1 expression in the treated group may protect the cavernous smooth muscle and endothelial cells from the harmful effect of high serum cholesterol.

L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:722933 CAPLUS <<LOGINID::20061110>>

DN 131:332126

TI Muscle-derived cell mediated gene delivery for treating muscle- and bone-related injury or dysfunction

IN Chancellor, Michael B.; Huard, Johnny

PA University of Pittsburgh, USA

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO.

DATE

PI WO 9956785 A2 19991111 WO 1999-US9451

19990430

WO 9956785 A3 20010419

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,

CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,

IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,

MG, MK,

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,

SK, SL, TJ,

TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH,

CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2330660 AA 19991111 CA 1999-2330660

19990430

AU 9937757 A1 19991123 AU 1999-37757

19990430

EP 1113807 A2 20010711 EP 1999-920202

19990430

R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT, IE, FI

US 6866842 B1 20050315 US 1999-302896

19990430

EP 1604674 A2 20051214 EP 2005-57

19990430

EP 1604674 A3 20051221

R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT, IE, FI

US 2005265978 A1 20051201 US 2005-40900

20050121

PRAI US 1998-83917P P 19980501

EP 1999-920202 A3 19990430

US 1999-302896 A3 19990430

WO 1999-US9451 W 19990430

AB The invention provides muscle-derived cells, preferably myoblasts and

muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting prodn. of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, ***basic*** ***fibroblast*** ***growth*** ***factor***, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-.beta., transforming growth factor-.alpha., nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

=> s female (3a) (sexual disorder or arousal dysfunction)
L7 41 FEMALE (3A) (SEXUAL DISORDER OR AROUSAL DYSFUNCTION)

=> s hia
L8 940 HIA

=> d his

(FILE 'HOME' ENTERED AT 16:45:48 ON 10 NOV 2006)

FILE 'EMBASE, BIOSIS, CAPLUS' ENTERED AT 17:04:32 ON 10 NOV 2006
L1 36990 S BFGF OR BASIC FIBROBLAST GROWTH FACTOR
L2 21530 S IMPOTEN?
L3 15377 S ERECTILE (3A) (DISORDER OR DYSFUNCTION OR DISEASE OR INAB?)
L4 29587 S L2 OR L3
L5 28 S L1 AND L4
L6 22 DUP REM L5 (6 DUPLICATES REMOVED)
L7 41 S FEMALE (3A) (SEXUAL DISORDER OR AROUSAL DYSFUNCTION)
L8 940 S HIA

=> s l1 and l7
L9 0 L1 AND L7

=>

--Logging off of STN--

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY SESSION	
FULL ESTIMATED COST	104.98	111.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

	ENTRY SESSION
CA SUBSCRIBER PRICE	-9.00 -9.00

STN INTERNATIONAL LOGOFF AT 17:11:10 ON 10 NOV 2006